Callisto Pharmaceuticals Announces $3.02 Million Private Placement

Callisto Pharmaceuticals, a biopharmaceutical company focused on the development of drugs to treat cancer and osteolytic bone disease, announced the completion of a private placement of approximately 1.99 million shares of its common stock at a per share price of $1.52, for aggregate gross proceeds of approximately $3.02 million. The financing was led by current institutional shareholders and included certain members of the company's management.

Market Wire (http://www.marketwire.com/mw/release_html_b1?release_id=82434)